Concepedia

Author

Ahmed Sawas

Columbia University Irving Medical CenterORCID

Also Known As

A H Sawas, A. Sawas, AHMED SAWAS, Ahmed Sawas, Sawas, Ahmed

131

Publications

2K

Citations

20

H-Index

40

Concepts

All Affiliations

Columbia University Irving Medical CenterColumbia UniversityMemorial Sloan Kettering Cancer CenterMayo Clinic in ArizonaDana-Farber Cancer Institute
AS

About

Ahmed Sawas is an author at Columbia University Irving Medical Center specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

294

2

Health Sciences

1

1

22

3

Cellular Therapies

1

1

33

4

Emergency Medicine

1

1

78

5

Gastroenterology

1

1

15

Ahmed Sawas

×

27

Publications

1.5K

Citations

16

H-Index

YearCitations

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas,

Blood

2018

246

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin,

Clinical Cancer Research

2021

183

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

Jennifer E. Amengual, Renee Lichtenstein, Jennifer Kimberly Lue,

Blood

2017

128

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue,

Blood

2019

127

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial

Owen A. O’Connor, Jennifer Kimberly Lue, Ahmed Sawas,

The Lancet Oncology

2017

113

Targeting CD47 in Sézary syndrome with SIRPαFc

Lisa D. Johnson, Swati Banerjee, Oleg Kruglov,

Blood Advances

2019

94

Triage and Outcome of Patients with Mediastinal Penetrating Trauma

Joshua H. Burack, Emad Kandil, Ahmed Sawas,

The Annals of Thoracic Surgery

2007

78

A phase 1/2 trial of ublituximab, a novel anti‐ <scp>CD</scp> 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab

Ahmed Sawas, Charles M. Farber, Marshall T. Schreeder,

British Journal of Haematology

2017

72

Mogamulizumab <i>versus</i> investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma

Adrienne A. Phillips, Paul Fields, Olivier Hermine,

Haematologica

2018

67

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, Gregory Bociek, Ahmed Sawas,

Blood

2015

61

Page 1